Biomarkers for Chronic Heart Failure

Lainščak, Mitja; Anker, Markus S.; Haehling, Stephan von; Anker, Stefan D.

doi:10.1007/s00059-009-3316-4

Cited by 38 publications

(16 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have shown that factors such as the inflammatory status, poor nutritional state and, obviously, the extent of cardiac dysfunction herald a poor prognosis in CHF [7][8][9][10][11][12][13]. However, none of these conventional indicators and, interestingly, also not LVF or RVF, carried any prognostic potential in our patient group.…”

Section: Discussionmentioning

confidence: 59%

Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis

Lindner

Doberer

Vychytil

et al. 2009

Wien Klin Wochenschr

View full text Add to dashboard Cite

Non-critically ill CHF patients with (sub-)acute renal dysfunction progressing to dialysis dependency have a grave prognosis. Renal failure itself had such a strong prognostic impact that conventional factors such as poor myocardial function or inflammation were concealed. Recovery of renal function and, surprisingly, anemia were beneficial factors. Alternative treatment strategies must be designed to improve the devastating prognosis for this special subset of patients with CHF.

show abstract

Section: Discussionmentioning

confidence: 59%

Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis

Lindner

Doberer

Vychytil

et al. 2009

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…Similar to several other biomarkers [4,5], increased circulating levels of pro-inflammatory cytokines have been shown to be closely related to the worsening of the patients' clinical symptoms and to predict poor short- [6] and long-term survival [7,8].…”

Section: Role Of Cytokines In Chronic Heart Failurementioning

confidence: 96%

The Gut and Intestinal Bacteria in Chronic Heart Failure

Sandek¹,

Anker²,

Haehling

2009

CDM

View full text Add to dashboard Cite

Chronic heart failure (CHF) is now recognized as a multisystem disorder with increased sympathetic tone, hormonal derangements, an anabolic/catabolic imbalance, endothelial dysfunction, and systemic low-grade inflammation affecting various organ systems. Pro-inflammatory cytokines appear to play important roles in that context. There is increasing evidence for the gut to have a pathophysiological role for both chronic inflammation and malnutrition in CHF. Indeed, disturbed intestinal microcirculation and barrier function in CHF seem to trigger cytokine generation, thereby contributing to further impairment in cardiac function. On the other hand, myocardial dysfunction can induce microcirculatory injuries leading to a disruption in the intestinal barrier. This amplifies the inflammatory response. Furthermore, alterations of specific absorption functions of the intestinal mucosa in CHF may aggravate symptoms of cachexia. The increased number of adherent bacteria seen in patients with CHF and elevated systemic levels of anti-lipopolysaccharide immunoglobulin A underscore this fact. Therefore, the gut poses an interesting target for therapeutic interventions in patients with CHF.

show abstract

“…Nonetheless, we detected cytoplasmatic proteins, which are involved in relevant pathological processes. Troponin T has been demonstrates as most reliable to detect and estimate the extent of cardiac damage [37]. Apolipoprotein E, tropomyosins, alpha-2 macroglobulin, complement 3, creatin kinase B and ceruloplasmin have been also described as biomarkers for chronic heart failure [38]–[42].…”

Section: Discussionmentioning

confidence: 99%

DIGE Proteome Analysis Reveals Suitability of Ischemic Cardiac In Vitro Model for Studying Cellular Response to Acute Ischemia and Regeneration

et al. 2012

View full text Add to dashboard Cite

Proteomic analysis of myocardial tissue from patient population is suited to yield insights into cellular and molecular mechanisms taking place in cardiovascular diseases. However, it has been limited by small sized biopsies and complicated by high variances between patients. Therefore, there is a high demand for suitable model systems with the capability to simulate ischemic and cardiotoxic effects in vitro, under defined conditions. In this context, we established an in vitro ischemia/reperfusion cardiac disease model based on the contractile HL-1 cell line. To identify pathways involved in the cellular alterations induced by ischemia and thereby defining disease-specific biomarkers and potential target structures for new drug candidates we used fluorescence 2D-difference gel electrophoresis. By comparing spot density changes in ischemic and reperfusion samples we detected several protein spots that were differentially abundant. Using MALDI-TOF/TOF-MS and ESI-MS the proteins were identified and subsequently grouped by functionality. Most prominent were changes in apoptosis signalling, cell structure and energy-metabolism. Alterations were confirmed by analysis of human biopsies from patients with ischemic cardiomyopathy.With the establishment of our in vitro disease model for ischemia injury target identification via proteomic research becomes independent from rare human material and will create new possibilities in cardiac research.

show abstract

Biomarkers for Chronic Heart Failure

Cited by 38 publications

References 56 publications

Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis

Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis

The Gut and Intestinal Bacteria in Chronic Heart Failure

DIGE Proteome Analysis Reveals Suitability of Ischemic Cardiac In Vitro Model for Studying Cellular Response to Acute Ischemia and Regeneration

Contact Info

Product

Resources

About